With a compelling hypothesis and sufficient mechanistic evidence in hand to link cisplatin to the glucocorticoid receptor, the team went on to study whether the MAST1 inhibitor, Lestaurtinib, could resensitize tumor cells to cisplatin while preserving alternative supported pathways and thus potentially beneficial effects of the glucocorticoid receptor. The gene discussed is NR3C1; the disease is neoplasm.